Because TGFβ1 is known to compromise CTL effector function, several trials have been designed to investigate whether introducing TGFβ1 resistance into adoptively-transferred CTL can boost the anti-tumor efficacy of these cells. The gene discussed is TGFB1; the disease is neoplasm.